Santaris Sues Mirrx Founder Over Blockmir Technology
May 06, 2010
Santaris Sues Mirrx Founder Over Blockmir Technology
In his defense, Mirrx's founder charged that Santaris is aiming to gain control of the Blockmir technology as an alternative to the LNA technology used in its phase I HCV drug SPC3649, which he alleges falls under intellectual property controlled by Regulus Therapeutics.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- EPO to Hear Mirrx Request for Resumption of Patent Proceedings Covering miRNA Rx Technology
January 20, 2011 / Gene Silencing News - EPO Rejects Mirrx Bid to Reinstate Patent Proceedings Ahead of Ruling on Suit with Santaris
July 21, 2011 / Gene Silencing News - UNC Teams Uncovers How HCV Uses miR-122 to Survive
January 5, 2012 / Gene Silencing News - Santaris Nears End of Phase II Trial of miRNA HCV Rx, Seeks Partnership Since GSK Opted Out
September 15, 2011 / Gene Silencing News - Santaris Pharma to Begin Phase II Development of miRNA-Targeting HCV Drug
September 23, 2010 / Gene Silencing News